Everstack Evidence

BLast reviewed

NR and NMN: raising NAD+ is not the same as slowing aging

B for raising NAD+ levels (replicated randomized trials). D for functional or long-term outcomes, which are not established.

Published Sources checked 2 sourcesEverstack research teamHow we work

A cell under fluorescence microscopy: the red network is its mitochondria, the blue is the nucleus
A cell under fluorescence microscopy: the red network is its mitochondria, the blue is the nucleus. Image: NICHD, National Institutes of Health, Public domain

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.

The question
Do NAD+ precursors raise NAD+ in people, and does that change how people function?
Study design
Randomized crossover trial of NR 1,000 mg/day in 24 healthy middle-aged and older adults (2018). NR trial in aged men with skeletal muscle biopsies (2019). [1][2]
What they found
NR was well tolerated and raised blood NAD+ levels. Changes in physical function were not significant in these short trials. [1][2]
Limitations
Short trials, small samples, surrogate markers. NMN became lawful as a supplement again in September 2025 but remains a New Dietary Ingredient; we only consider suppliers covered by an acknowledged notification.
What this does not mean
Higher NAD+ in blood does not mean slower aging. Anyone who tells you otherwise is ahead of the evidence.
Sources
  1. Martens CR et al. Nat Commun. 2018;9:1286. doi.org/10.1038/s41467-018-03421-7
  2. Elhassan YS et al. Cell Rep. 2019;28(7):1717-1728. doi.org/10.1016/j.celrep.2019.07.043

Where it is discussed on podcasts

Verified episodes. Hosts and guests do not endorse Everstack. Podcast index

Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.